KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Other Non Operating Income (2023 - 2025)

Biocryst Pharmaceuticals' Other Non Operating Income history spans 8 years, with the latest figure at $6.8 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 1154.45% year-over-year to $6.8 million; the TTM value through Dec 2025 reached $4.0 million, up 683.63%, while the annual FY2025 figure was -$152000.0, 76.29% up from the prior year.
  • Other Non Operating Income reached $6.8 million in Q4 2025 per BCRX's latest filing, up from -$2.7 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $6.8 million in Q4 2025 to a low of -$2.7 million in Q3 2025.
  • Average Other Non Operating Income over 3 years is $153222.2, with a median of -$63000.0 recorded in 2025.
  • The largest YoY upside for Other Non Operating Income was 1154.45% in 2025 against a maximum downside of 2895.92% in 2025.
  • A 3-year view of Other Non Operating Income shows it stood at -$1.9 million in 2023, then skyrocketed by 66.26% to -$641000.0 in 2024, then surged by 1154.45% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Other Non Operating Income are $6.8 million (Q4 2025), -$2.7 million (Q3 2025), and -$63000.0 (Q2 2025).